RecruitingPhase 2NCT06822972
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
Studying Plasma cell tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Duke University
- Principal Investigator
- Yubin Kang, MDDuke Health
- Intervention
- Selinexor 40 mg(drug)
- Enrollment
- 27 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2027
Study locations (1)
- Duke University Health System, Durham, North Carolina, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06822972 on ClinicalTrials.govOther trials for Plasma cell tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07446777FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor DiseaseUniversity of Miami
- RECRUITINGPHASE1NCT07333261Study of BMS-986453 in Newly Diagnosed Multiple MyelomaSusan Bal
- RECRUITINGPHASE3NCT07258511A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple MyelomaJanssen Research & Development, LLC
- RECRUITINGPHASE1NCT07093554Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple MyelomaMedical College of Wisconsin
- RECRUITINGPHASE2NCT06920251Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab TherapySeoul National University Hospital
- RECRUITINGNANCT07045727Prehabilitation With Aerobic and Resistance Exercise for Improving Physical Fitness and Quality of Life Outcomes in Older Patients Undergoing CAR-T Therapy for Relapsed or Refractory Multiple MyelomaMayo Clinic
- ENROLLING BY INVITATIONPHASE1, PHASE2NCT07210047Study of HuL001 in Relapsed/Refractory Multiple Myeloma PatientsHuniLife Biotechnology, Inc.
- RECRUITINGPHASE2NCT07106736MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple MyelomaInstitute of Hematology & Blood Diseases Hospital, China